概括
目前的阿尔茨海默病 (AD) 治疗重点是症状. 新的粉样蛋白降低疗法显示出减缓疾病的潜力,但需要对副作用进行监测,提供了一种超出症状管理的新方法.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 长期以来,症状治疗一直是阿尔茨海默病 (AD) 药物治疗的标准.
- 新兴的疗法旨在修改疾病的潜在病理.
研究的目的:
- 审查当前阿尔茨海默病的症状治疗的证据.
- 检查具有潜在疾病减缓效果的新兴粉样蛋白降低疗法.
主要方法:
- 对乙胆酶抑制剂和记忆剂的证据的审查.
- 对最近批准的粉样蛋白降低单克隆抗体 (lecanemab,donanemab) 的数据分析.
- 检查FDA批准的治疗动荡 (brexpiprazole) 和失眠 (suvorexant) 在AD.
主要成果:
- 乙胆酶抑制剂对于轻度至重度的AD痴呆症有强有力的证据,延迟认知和功能衰退.
- 孟曼丁对中度至重度的AD有支持的证据.
- 粉样蛋白降低疗法是FDA批准的第一个改变AD病理的选择,具有减缓AD进展的潜力,但存在粉样蛋白相关成像异常的风险.
- 对阿尔茨海默病行为症状的药物治疗具有有限的可预测疗效.
结论:
- 虽然症状治疗有好处,但粉样蛋白降低疗法在改变AD病理方面取得了重大进展.
- 了解抗粉胺疗法的长期效用和患者价值仍在发展.
- 由于潜在的不良事件,对粉样蛋白降低疗法进行仔细的安全监测至关重要.
更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.2K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
相关概念视频
01:22Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
01:26Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
01:24Parkinson's Disease: Treatment
219
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
219
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
96
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
96
01:15Parkinson's Disease: Overview
479
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
479
01:30Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96